Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Payables (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Payables readings, the most recent being $4.4 million for Q4 2023.

  • On a quarterly basis, Payables rose 55.76% to $4.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $4.4 million, a 55.76% increase, with the full-year FY2023 number at $4.4 million, up 55.76% from a year prior.
  • Payables hit $4.4 million in Q4 2023 for Elicio Therapeutics, down from $4.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $56.7 million in Q4 2020 to a low of $692000.0 in Q1 2023.
  • Median Payables over the past 4 years was $4.4 million (2023), compared with a mean of $8.5 million.
  • Biggest five-year swings in Payables: tumbled 91.7% in 2021 and later skyrocketed 98.65% in 2023.
  • Elicio Therapeutics' Payables stood at $56.7 million in 2020, then tumbled by 91.7% to $4.7 million in 2021, then tumbled by 40.45% to $2.8 million in 2022, then soared by 55.76% to $4.4 million in 2023.
  • The last three reported values for Payables were $4.4 million (Q4 2023), $4.4 million (Q3 2023), and $4.3 million (Q2 2023) per Business Quant data.